Italia markets open in 7 hours 25 minutes

Amicus Therapeutics, Inc. (0HF9.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
13,43+0,63 (+4,92%)
Alla chiusura: 06:56PM GMT
Schermo intero
Chiusura precedente12,80
Aperto12,95
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno12,95 - 13,56
Intervallo di 52 settimane9,74 - 14,57
Volume848
Media Volume840
Capitalizzazione39,364M
Beta (5 anni mensile)0,76
Rapporto PE (ttm)N/D
EPS (ttm)-0,97
Prossima data utili08 mag 2024 - 13 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023

    PRINCETON, N.J., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and four posters highlighting its development program for Pompe disease will be included at the 28th Annual Congress of the World Muscle Society (WMS), being held October 3-7, 2023 in Charleston, SC. Oral Presentation: Abstract Title: 104-week efficacy and safety of cipaglucosidase alfa + miglustat in patients with late-onset Pompe disease previously treated with algl

  • GlobeNewswire

    Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration

    Refinancing of Current $400M Debt at Lower Cost and Improved Amortization Schedule Blackstone to also Purchase $30M of Amicus Common Stock PRINCETON, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases, today announced that it has entered into a definitive agreement for a $430 million financing collaboration with funds managed by Blackston

  • GlobeNewswire

    Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease

    Pombiliti + Opfolda Logo Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) Approved in ERT-Experienced Adults First and Only Two-Component Therapy for Eligible Adults Living with Late-onset Pompe Disease Amicus Therapeutics to Host Conference Call Today at 12:00 p.m. ET PHILADELPHIA, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has approved Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (migl